Highbridge Capital Management LLC Makes New $3.44 Million Investment in OnKure Therapeutics (NASDAQ:OKUR)

Highbridge Capital Management LLC bought a new stake in OnKure Therapeutics (NASDAQ:OKUR) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 399,743 shares of the company’s stock, valued at approximately $3,438,000. Highbridge Capital Management LLC owned approximately 11.96% of OnKure Therapeutics at the end of the most recent reporting period.

Wall Street Analyst Weigh In

Several analysts recently issued reports on OKUR shares. Oppenheimer dropped their price objective on shares of OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research note on Tuesday, March 11th. Leerink Partnrs upgraded OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. HC Wainwright cut their price target on OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating for the company in a report on Tuesday, March 18th. Finally, Leerink Partners began coverage on OnKure Therapeutics in a research note on Thursday, December 5th. They set an “outperform” rating and a $33.00 price objective on the stock. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $32.33.

OnKure Therapeutics Stock Down 1.1 %

NASDAQ:OKUR opened at $4.69 on Friday. The company has a 50-day moving average price of $5.30. OnKure Therapeutics has a 1-year low of $4.45 and a 1-year high of $20.00. The firm has a market cap of $63.01 million, a price-to-earnings ratio of -0.38 and a beta of 0.28.

OnKure Therapeutics (NASDAQ:OKUR) last released its quarterly earnings data on Monday, March 10th. The company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51). Sell-side analysts anticipate that OnKure Therapeutics will post -4.05 EPS for the current year.

OnKure Therapeutics Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.